Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

美时（1795）20日宣布，美国FDA已接受 Voclosporin 软胶囊的潜在首家简化新药申请（ANDA），原厂药物为 AuriniaPharmaceuticals Inc. 的 Lupkynis®。Lupkynis® 是第一个也是唯一一个获 FDA 批准用于治疗狼疮肾炎（lu ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.

美时(1795)今(20)日宣布，美国食品药品监督管理局(FDA)已接受Voclosporin软胶囊的潜在首家简化新药申请(ANDA)，原厂药物为Aurinia Pharmaceuticals Inc.的Lupkynis。Lupkynis是第一个也是唯一一个获FDA批准用于治疗 ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio ’s CAR T-cell therapy for ...